• 1. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzyloxycarbonyls

Introduction to N-alpha-Boc-Nepsilon-Z-L-lysine dicyclohexylammonium Salt (CAS No. 16948-04-2)

N-alpha-Boc-Nepsilon-Z-L-lysine dicyclohexylammonium salt is a highly specialized chemical compound that has garnered significant attention in the field of pharmaceutical research and biotechnology. This compound, identified by its CAS number 16948-04-2, is a critical intermediate in the synthesis of various bioactive molecules, particularly in the development of peptide-based drugs and enzyme inhibitors. The unique structural features of this compound make it an invaluable tool for researchers aiming to manipulate and study complex biological pathways.

The molecular structure of N-alpha-Boc-Nepsilon-Z-L-lysine dicyclohexylammonium salt consists of a protected lysine residue, where both the alpha-amino group and the epsilon-amino group are modified. The Boc (tert-butoxycarbonyl) group provides stability to the amino group, while the Z (carboxybenzyloxy) group protects the epsilon-carboxylate group. This dual protection strategy allows for selective functionalization at different sites, making it a versatile building block in peptide synthesis. The dicyclohexylammonium salt form enhances solubility and handling properties, facilitating its use in various organic reactions and solid-phase peptide synthesis (SPPS).

In recent years, there has been a surge in research focused on developing novel therapeutic agents based on peptides. Peptides offer several advantages over traditional small-molecule drugs, including higher specificity and lower toxicity. N-alpha-Boc-Nepsilon-Z-L-lysine dicyclohexylammonium salt plays a pivotal role in this landscape by enabling the efficient synthesis of complex peptide sequences. For instance, it has been widely used in the development of peptidomimetics, which mimic the structure and function of natural peptides but with improved pharmacokinetic properties.

One of the most compelling applications of this compound is in the field of enzyme inhibition. Many therapeutic targets are enzymes that play crucial roles in disease pathways. By designing peptides that can bind to these enzymes and modulate their activity, researchers can develop treatments for conditions such as cancer, inflammation, and infectious diseases. N-alpha-Boc-Nepsilon-Z-L-lysine dicyclohexylammonium salt provides a scaffold for creating such inhibitory peptides, allowing for precise tuning of binding affinity and selectivity.

The importance of this compound is further underscored by its use in drug discovery pipelines. Pharmaceutical companies and academic institutions alike rely on high-quality intermediates like N-alpha-Boc-Nepsilon-Z-L-lysine dicyclohexylammonium salt to accelerate their research programs. The ability to synthesize large libraries of peptide derivatives efficiently is crucial for identifying lead compounds that can be further optimized into viable drugs. This compound’s stability and reactivity profile make it an ideal candidate for such applications.

Recent advancements in synthetic chemistry have also expanded the utility of N-alpha-Boc-Nepsilon-Z-L-lysine dicyclohexylammonium salt. Techniques such as solid-phase peptide synthesis (SPPS) have been refined to allow for automated and scalable production of complex peptides. The use of this intermediate has streamlined these processes, reducing both time-to-market and production costs. Additionally, innovations in purification methods have improved the quality and consistency of peptide products derived from this compound.

The role of N-alpha-Boc-Nepsilon-Z-L-lysine dicyclohexylammonium salt extends beyond drug development into fundamental biological research. Peptide-based probes are increasingly used to study protein-protein interactions, cellular signaling pathways, and other critical biological processes. By incorporating this compound into synthetic peptides, researchers can design tools that provide insights into these mechanisms at a molecular level. Such studies are essential for understanding disease mechanisms and developing targeted therapies.

In conclusion, N-alpha-Boc-Nepsilon-Z-L-lysine dicyclohexylammonium salt (CAS No. 16948-04-2) is a cornerstone compound in modern peptidic chemistry. Its unique structural features and versatile reactivity make it indispensable for synthesizing bioactive molecules with therapeutic potential. As research continues to uncover new applications for peptides and peptidomimetics, the demand for high-quality intermediates like this one will only grow. The ongoing advancements in synthetic methodologies further enhance its value, ensuring its continued relevance in pharmaceutical and biotechnological applications.

• 2389-45-9((S)-6-(((Benzyloxy)carbonyl)amino)-2-((tert-butoxycarbonyl)amino)hexanoic acid)
• 3160-59-6(N-Cbz-L-isoleucine)
• 15027-14-2(Z-D-norleucine)
• 2640-58-6(N2-Benzyloxycarbonyl-L-ornithine)
• 28862-79-5(D-N-(Benzyloxycarbonyl)leucine)
• 21691-44-1(Z-L-norvaline)
• 13574-13-5((2S)-5-benzyloxy-2-(tert-butoxycarbonylamino)-5-oxo-pentanoic acid)
• 2018-66-8(N-Cbz-L-leucine)
• 1155-62-0(N-Carbobenzoxy-L-glutamic acid)
• 2212-75-1(Z-Lys-OH)